Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 18, Issue 2, 1998, Pages 117-125

  Eldred, Lois J ^a,c   Wu, Albert W ^b   Chaisson, Richard E ^a   Moore, Richard D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c AIDS Administration   (United States)

Author keywords

Adherence; Antiretroviral therapy; Compliance; HIV; Pneumocystis carinii prophylaxis

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DAPSONE; PENTAMIDINE;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PATIENT COMPLIANCE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SELF REPORT;

HUMAN IMMUNODEFICIENCY VIRUS; PNEUMOCYSTIS; PNEUMOCYSTIS CARINII; PROTOZOA; RNA VIRUSES;

EID: 0032102094     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199806010-00003     Document Type: Article

References (57)

1. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med 1995;333:1528-33.
2. Gullick R, Mellors J, Havlir D, et al. Potent and sustained antiretroviral activity of indinavir in combination with zidovudine and lamivudine [abstract]. Third Conference on Retroviruses and Opportunistic Infections. Infectious Disease Society of America, National Institutes of Health, and the Centers for Disease Prevention and Control, January 29-February 1, 1996, Washington, D.C.
3. Massari F, Conant M, Mellors J, et al. A phase II open-label, randomized study of the triple combination of indinavir, zidovudine, didanosine versus indinavir alone and zidovudine/didanosine alone and zidovudine/didanosine in antiretroviral naive patients [abstract]. Third Conference on Retroviruses and Opportunistic Infections. Infectious Disease Society of America, National Institutes of Health, and the Centers for Disease Prevention and Control, January-February 1, 1996, Washington, D.C.
4. Cameron B, Heath-Chiozzi M, Kravei S, et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir [abstract]. Third Conference on Retroviruses and Opportunistic Infections. Infectious Disease Society of America, National Institutes of Health, and the Centers for Disease Prevention and Control, January-February 1, 1996, Washington, D.C.
5. Kitchen VS, Skinner C, Ariyoshi K, et al. Safety and activity of saquinavir in HIV infection. Lancet 1995;345:952-5.
6. + T-cell counts in HIV-infected patients. Ann Intern Med 1996;124:1039-50.
7. Fischl NM, Dickinson GK, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988;259:1185-9.
8. Chaisson RE, Keruly J, Richman DD, Moore RD. Zidovudine Epidemiology Study Group. Pneumocystis carinii prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. Arch Intern Med 1992;152: 2009-13.
9. Kovacs JA, Masur J. Prophylaxis for Pneumocystis carinii pneumonia in patients infected with the human immunodeficiency virus. Clin Infect Dis 1992;14(5):1005-9.
10. Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med 1994; 120:932-44.
11. Graham NM, Zeger SL, Park L, et al. The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med 1992;326(16):1037-42.
12. Graham NM, Zeger SL, Park LP, et al. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS: The Multicenter AIDS Cohort Study. Lancet 1991;338:265-9.
13. Sackett DL, Snow JS. The magnitude of compliance and noncompliance. In Haynes RB, Taylor DW, Sackett DI, eds. Compliance in health care. Baltimore: Johns Hopkins University Press, 1979: 11-22.
14. Finnerty FA, Shaw LW, Himmelsbach CK. Hypertension in the inner city. II. Detection and follow-up. Circulation 1973;47:76-8.
15. Wilber JA, Barrow JG. Hypertension - a community problem. Am J Med 1972;52:653-6.
16. McKenney JM, Slining JM, Henderson HR, Devines D, Barr M. The effect on clinical pharmacy services on patients with essential hypertension. Circulation 1973;48:1104-11.
17. Rudnick KV, Sackett DL, Hirst S. Hypertension in a family practice. Can Med Assoc J 1977;117:492-7.
18. Samuels JE, Hendrix J, Hilton M, Marantz PR, Sloan V, Small CB. Zidovudine therapy in an inner city population. J Acquir Immune Defic Syndr 1990;3:877-83.
19. Samet JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med 1992;92:495-502.
20. Broers B, Morabia A. Hirschel B. A cohort study of drug users' compliance with zidovudine treatment. Arch Intern Med 1994;154: 1121-7.
21. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Avorn J. Noncompliance with congestive heart failure therapy in the elderly. Arch Intern Med 1994;330:763-8.
22. Rand CS, Wise RA. Measuring adherence to asthma medication regimens. Am J Respir Crit Care Med 1994;149:S69-76.
23. Haynes RB. Determinants of compliance: the disease and the mechanics of treatment. In Haynes RB, Taylor DW, Sackett DL. Compliance in health care. Baltimore: Johns Hopkins University Press, 1979:46-62.
24. Mushlin AL, Appel FA. Diagnosing potential noncompliance. Arch Intern Med 1977;137:318-21.
25. Roth HP, Caron HS. Accuracy of doctors' estimates and patients' statements on adherence to a drug regimen. Clin Pharmacol Ther 1978;23:361-70.
26. Norell SE. Accuracy of patient interviews and estimates by clinical staff in determining medication compliance. Soc Sci Med 1981;15: 57-61.
27. Berwick DM, Murphy JM, Goldman PA, Ware JR, Barsky AJ, Weinstein MC. Performance of a five-item mental health screening test. Med Care 1991;29:169-76.
28. Bratton AC, Marshall EK Jr. A new coupling component for sulfanilamide determination. J Biol Chem 1939;128:537-50.
29. Kremers P, Duvivier J, Heusghem C. Pharmacokinetic studies of co-trimazole in man after single and repeated doses. J Clin Pharm 1974;14:112-17.
30. Kaplan SA, Weinfeld RE, Abruzzo CW, et al. Pharmacokinetic profile of trimethoprim-sulfamethoxazole in man. J Infect Dis 1973:S547-55.
31. Singh N, Squier C, Sivek C, Wagener M, Hong Nguyen M, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: a prospective assessment with implications for enhancing compliance. AIDS Care 1996;8: 261-9.
32. Kraemer JC. Kappa coefficient. In Kotz S, Johnson J, eds. Encyclopedia of statistical sciences. New York: John Wiley & Sons, 1982.
33. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometricka 1951;16:297-34.
34. Nunnally JC. Psychometric theory. New York: McGraw-Hill, 1978.
35. Haynes RB, Taylor DW, Sackett DL, et al. Can simple clinical measurements detect patient noncompliance? Hypertension 1980; 2:757-64.
36. Besch LC. Compliance in clinical trials. AIDS 1995;9:1-10.
37. Sumartojo E. When tuberculosis treatment fails. A social behavior account of patient adherence. Am Rev Respir Dis 1993;147:1311-20.
38. Stryker J, Coates TJ, DeCarlo P, Haynes-Sonstad K, Shriver M, Makadow HJ. Prevention of HIV infection. Looking back, looking ahead. JAMA 1994;273:1143-8.
39. Zenilman JM, Erickson B, Fox MS, Reichart C, Hook EM. Effect of HIV posttest counseling on STD incidence. JAMA 1992;267: 843-5.
40. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:1881-4.
41. Kruse W, Eggert-Kruse W, Rampmaier J, Runnebaum B, Weber E. Dosage frequency and drug-compliance behavior - a comparative study on compliance with a medication to be taken twice or four times daily. Eur J Clin Pharmacol 1991;41:589-92.
42. Skaer TL, Sclar DA, Robison LM, et al. Effect of pharmaceutical formulation for antihypertensive therapy on health services utilization. Clin Ther 1993;15:715-25.
43. Bandura A, Self-efficacy mechanism in human agency. Am Psychol 1982;37:122-47.
44. Stretcher JV, DeVellis BM, Becker MH, Rosenstock IM. The role of self-efficacy in achieving health behavior change. Health Educ Q 1986;13:73-91.
45. Prochaska JO, Crimi P, Lapanski D, et al. Self-changes processes, self-efficacy and self-concept in relapse and maintenance of cessation of smoking. Psychol Rep 1982;51:983-90.
46. Tedesco LA, Keffer MA, Fleck-Kandath C. Self-efficacy, reasoned action and oral health behavior reports: a social cognitive approach to compliance. J Behav Med 1991;14:341-55.
47. DiClementi CC, Prochaska JA, Gibertini M. Self-efficacy and the chances of self-change of smoking. Cogn Ther Res 1985;9:181-200.
48. Edell BH, Edington S, Herd B, O'Brien RM, Witkin G. Self-efficacy and self-motivation as predictors of weight loss. Addict Behav 1987;12:63-6.
49. Schunk D, Carbonari J. Self-efficacy models. In Matarazzo J, Weiss S, Herd J, Miller N, Weiss S, eds. Behavioral health: a handbook of health enhancement and disease prevention. New York: John Wiley & Sons, 1984.
50. McIntyre DO, Lichtenstein E, Mermelstein RH. Self-efficacy and relapse in smoking cessation: a replication and extension. J Consult Clin Psychol 1983;51:632-3.
51. Condiotte W, Lichtenstein E. Self-efficacy and relapse in smoking cessation program. J Consult Clin Psychol 1981;49:648-58.
52. Gilchrist LD, Schinke SP. Coping with contraception: cognitive and behavioral methods with adolescents. Cogn Ther Res 1983;7: 379-88.
53. Ewart C, Taylor CD, Reese LB, Debusk RJ. Effects of early post-myocardial infarction exercise testing on self-perception and subsequent physical activity. Am J Cardiol 1984;41:1076-80.
54. Roter D, Hall J, Katz N. Patient-physician communication. A descriptive summary of the literature. Patient Edite Counsel 1988; 12:99.
55. Heszen-Klemens I, Lapinska E. Doctor-patient interaction, patients health behavior and effects of treatment. Soc Sci Med 1984;19:9-18.
56. Park LC, Lipman RS. A comparison of patient dosage deviation reports with pill counts. Psychopharmacologia 1964;6:229.
57. Cramer JA, Mattson JH, Prevey ML, Scheyer RD, Quellet VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3273-7.